The evaluation of yeast derivatives as adjuvants for the immune response to the Bm86 antigen in cattle by Rodriguez Valle, Manuel et al.
BMC Biotechnology (2001) 1:2 http://www.biomedcentral.com/1472-6750/1/2BMC Biotechnology (2001) 1:2Research article
The evaluation of yeast derivatives as adjuvants for the immune 
response to the Bm86 antigen in cattle
Manuel Rodríguez Valle*, Carlos Montero, Héctor Machado and 
Marisdania Joglar
Address:  Mammalian Cell Genetics Division, Centro de Ingeniería Genética y Biotecnología, P.O.Box 6162, Havana, Cuba
E-mail: Manuel Rodríguez Valle* - mrodriguez@cigb.edu.cu; Carlos Montero - carlos.montero@cigb.edu.cu; 
Héctor Machado - hmarchado@cigb.edu.cu; Marisdania Joglar - marisdania.joglar@cigb.edu.cu
*Corresponding author
Abstract
Background:  The Gavac™ vaccine against the cattle tick Boophilus microplus has proven its
efficacy in a large number of controlled and field experiments. However, this vaccine could be
further improved by searching for new alternative adjuvants that would induce a stronger long-
lasting immune response. We conducted several experiments to assay the adjuvant effect of
fractions of the recombinant yeast Pichia pastoris in mouse and cattle models. In previous
experiments, the combination of the yeast membrane with saponin was the most effective
formulation in stimulating the humoral immune response in mice, eliciting a response higher than
Montanide 888. The response was predominantly of the IgG1 isotype. Here, we evaluated the
response in cattle and compared the results with that obtained in mice.
Results:  Bm86 on the membrane of P. pastoris plus saponin produced high antibody titers in cattle,
though the protection level against tick infestations was lower when compared to Gavac™,
probably due to a decrease in the IgG1/IgG2 ratio. The predictive value of the mouse model was
studied through correlation analysis between the isotype levels in mice and the efficacy of
formulations in cattle. Good correlation was established between the level of antibodies in mice
and cattle, and between the amount of anti -Bm86 IgG1 in mice and the degree of protection in
cattle.
Conclusion:  Mouse model have the potential to predict immunogenicity and efficacy of
formulations in cattle. These results also support the use of the yeast expression system for
recombinant vaccine formulations, enabling the prediction of more cost - effective formulations.
Background
In the last seven decades, a great number of studies have
been devoted to the use of adjuvants to potentiate the im-
mune response to antigens. These efforts have been par-
ticularly important in recent years with the development
of synthetic, purified subunit and recombinant vaccines,
which are generally poor immunogens. Recent studies
describe the advantages of using saponin over oil emul-
sions, although the latter still constitutes the most com-
mercially available adjuvant for veterinary vaccines.
Recently, the B. microplus Bm86 antigen was isolated
and expressed in the yeast P. pastoris to prepare the re-
combinant vaccine Gavac™ (Heber Biotec S.A., Havana,
Cuba) [1,2]. This vaccine against cattle ticks contains 100
µg Bm86 per dose in 2 ml of a Montanide 888 / mineral
oil in water emulsion and has proven its efficacy in a
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[2,3,4,5]. However, this vaccine could be further im-
proved by searching for new alternative adjuvants that
would induce a stronger long -lasting immune response,
and a reduction in production cost.
The immunostimulating properties of some components
of certain species of yeast have been previously reported
[6,7]. The recombinant Bm86 antigen expressed in P.
pastoris remains associated to the plasma membrane
[1], that surrounds the protein with a hydrophobic envi-
ronment similar to that of oil emulsion or liposomes.
Taking advantage of this fact, we made several experi-
ments to test the adjuvant effect of fractions of the re-
combinant yeast in mice [8].
Here, we report the results obtained when we use yeast
derivatives as adjuvants for the immune response in cat-
tle, the analysis of the predictive potential of the mouse
model, and the effect of the quality of the immune re-
sponse on the degree of protection. The membrane of the
yeast P. pastoris was shown to serve as an adjuvant for
the humoral immune response in both animal species,
adding new advantages to the yeast expression system
for the production of recombinant vaccine formulations.
Results
Experiment I
Kinetics of the antibody response
Table 1 shows the results obtained in the quantification
by ELISA of the level of anti-Bm86 antibodies in the se-
rum samples from immunized mice [8]. Control groups
kept a basal level of Bm86-specific reactivity equal to
that of preimmune sera, indicating the specificity of the
assays. Mice injected with Bm86 in the membrane plus
saponin produced the highest serological response,
reaching an immunological peak on day 30. Animals
from the Bm86 / cell group showed practically no immu-
nological response against the Bm86 antigen (Table 1).
Quality of the immune response
Sera extracted on day 40 were chromatographed through
a column of Protein A Sepharose and the resulting peaks
were collected for analysis, which was restricted only to
subclasses IgG1, IgG2, and IgG2b, since the level of IgG3
was low and hardly varied among the different groups
[8].
The total amount of protein corresponding to each sub-
type was determined and thus expressed as the relative
level of antibodies (Table 2). The quantification level of
the different IgG isotypes from Bm86 / Montanide 888
or Bm86/ cell groups were similar, with a predominance
of IgG1 within the IgG subclasses. Groups immunized
with membrane plus saponin showed a higher propor-
tion of the IgG2 isotype, which was of over 30% of the to-
tal IgG content.
Forty days after the immunization, pooled sera were ti-
trated by ELISA to compare the relative amounts of anti-
Bm86 IgG subclasses in the vaccinated groups (Table 3).
The levels of Bm86-specific immunoglobulins showed a
pattern similar to that of total IgG. Cells produced low
levels of anti-Bm86 antibodies. In contrast, specific anti-
body levels were higher for groups injected with mem-
brane and with Montanide 888. In the group immunized
with the membrane plus saponin, the production of anti-
Bm86 IgG2a was strongly stimulated. In control groups
immunized with Dextranase-containing preparations,
no specific anti-Bm86 antibodies were detected.
Experiment II
Serology
In calves immunized with preparations containing
Bm86, high anti-Bm86 antibody titres were obtained
with the formulations based on Montanide 888 and the
membrane plus saponin, while the response obtained
with cells was extremely poor (Table 4). Although the sa-
ponin-based formulation produced an immune response
with a higher IgG2/IgG1 ratio than Gavac™, the levels of
the IgG isotypes were not significantly different between
both formulations (Table 4).
Response to challenge with tick larvae
Calves were challenged with 1000 larvae per animal per
day for three days two weeks after the third immuniza-
tion. The ability of each formulation to elicit a protective
immune response was determined and expressed as
overall efficacy (Table 5). The Montanide 888 adjuvant
produced the most effective response, while the percent-
age of tick control was very low in the groups immunized
with Bm86 associated to cells.
Mouse as a predictive model
The value of mice in predicting the immunogenicity of
Bm86 formulations in cattle was studied through a cor-
relation analysis of the response with the formulations
tested in both animal systems. At week 9 antibody levels
in cattle were correlated with mouse antibody levels at
day 30 or day 40, obtaining correlation coefficients of
0.96 and 0.99, respectively.
A relationship was established between the mean anti-
Bm86 IgG1 levels in mice and the protection reached in
cattle with each formulation, giving a correlation coeffi-
cient of 0.99.
In contrast, anti-Bm86 IgG2a levels in mice were poorly
correlated to protection in calves (R 2 = 0.49).
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Days
Immunogen / adjuvant 10 20 30 40
Bm86 / Montanide 888 0.23 ± 0.24 1.34 ± 0.58 2.17 ± 0.54 1.02 ± 0.12
Bm86 / cells 0.17 ± 0.05 0.16 ± 0.10 0.24 ± 0.31 0.25 ± 0.07
Bm86 / membrane 0.17 ± 0.07 1.20 ± 0.67 2.09 ± 0.48 1.09 ± 0.27
Bm86 / membrane / saponin 0.23 ± 0.09 2.16 ± 0.39 2.68 ± 0.18 1.09 ± 0.12
Cells 0.15 ± 0.07 0.07 ± 0.05 0.18 ± 0.06 0.19 ± 0.05
Membrane 0.22 ± 0.08 0.19 ± 0.11 0.26 ± 0.11 0.26 ± 0.14
Membrane / saponin 0.21 ± 0.06 0.12 ± 0.03 0.23 ± 0.08 0.25 ± 0.11
a Ten mice per group were immunized with 5 µg Bm86 adjuvated as indicated (Garcia - Garcia et al., 1995). ELISA was used to determine total 
antibody response against Bm86.Briefly, 100 µl of antiserum diluted 1: 100 in PBS were added to the wells, incubated for 2 h at 37°C, washed four 
time with PBST and developed with HRP-conjugated goat anti-mouse IgG as describe in material and methods. Antibody titres were expressed as 
the mean absorbance value (O.D.492nm) per group ± SD (N = 10).
Table 2: Experiment I. Immunoglobulin in mice immunized according to the experimental groupa.
Immunogen / adjuvant IgG1 IgG2a IgG2b Total IgG
Bm86 / Montanide 888 0.519 (71.39) b 0.128 (17.61) 0.080 (11.00) 0.727
Bm86 / cells 0.271 (60.90) 0.094 (21.12) 0.080 (17.98) 0.445
Bm86 / membrane 0.566 (74.57) 0.127 (16.73) 0.066 (8.70) 0.759
Bm86 / membrane / saponin 0.637 (54.17) 0.465 (39.54) 0.074 (6.29) 1.176
Cells 0.278 (66.03) 0.083 (19.72) 0.060 (14.25) 0.421
Membrane 0.498 (70.14) 0.170 (23.94) 0.042 (5.92) 0.710
Membrane / saponin 0.717 (67.64) 0.251 (23.68) 0.92 (8.68) 1.060
a Ten mice per group were immunized with 5 µg Bm86 (except the controls) adjuvated as indicated. Antibody levels were expressed as the absorb-
ance at 280 nm of the pooled serum samples at day 40 (Garcia - Garcia et al., 1995). b Within the parentheses the percent of the total IgG that 
corresponds to the subclass.
Table 3: Experiment I. Anti-Bm86 titer in the sera of mice immunized according to experimental groupsa.
IgG1/IgG2a
Immunogen / adjuvant IgG1 IgG2a IgG2b
Ratio
Bm86 / Montanide 888 2000 200 100 10
Bm86 / cells 32 4 8 8
Bm86 / membrane 400 <50 <50 >8
Bm86 / membrane / saponin 1000 400 100 2.5
a Experiments were conducted as described in Table 2. The IgG samples were homogenized to the same protein concentration and specific anti-
Bm86 antibody levels were determined by ELISA and expressed as antibodies titres (Garcia - Garcia et al.,1995).
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The B. microplus Bm86 antigen has been proven to in-
duce a protective immune response in immunized cattle
[1,2,4,5,9]. Furthermore, the control of tick populations
in the field is correlated to the level of anti-Bm86 anti-
bodies elicited by vaccination [4,10,11]. The vaccine de-
veloped by our group uses a recombinant Bm86 antigen
obtained from P. pastoris-expressing cells [1,2], which is
expressed while associated to the plasma membrane
[1,2]. Its hydrophobic microenvironment and the possi-
ble immunostimulating ability of certain components of
the yeast cell wall led us to evaluate the effect of using
some yeast derived preparations as the adjuvant of the
humoral immune response to the Bm86 antigen.
Table 4: Experiment II. Anti-Bm86 titer in immunized cattlea.
Immunogen / adjuvant Total IgG IgG1 IgG2
Bm86 / Montanide 888 23 744 11 763 1 114
Bm86 / cells 44 N/D N/D
Bm86 / membrane / saponin 24 639 8 611 2 560
a Three cross-bred Holstein calves per group were immunized with 100 µg Bm86 (except the controls) adjuvated as indicated. Antibody titers are 
expressed as the geometric mean titer determined by LISA.
Table 5: Experiment II. Protection of vaccinated calves against tick infestationsa.
Percent of reduction of
Immunogen / adjuvant Tick Tick Egg Efficacyf
Numberb WeightC laying Fertilitye (%)
Capacityd
Bm86 / Montanide 888 35 45 61 40 85
Bm86 / cells 0 6 14 0 14
Bm86 / membrane / saponin 18 26 27 30 58
a Experiments were conducted as described in Table 4. b Percent reduction of the adult female ticks. cPercent reduction on the mean weight of the 
engorged tick. d Percent reduction in the laying capacity of the adult female ticks. e Percent reduction in the mean weight of the larvae per gram of 
eggs. f Efficacy (%) = 100 × {1- (CRT × CRO × CRF)}; CRT: Reduction in the number of engorging ticks; CRO: Reduction in the egg laying capacity; 
CRF: Reduction in fertility.
Table 6: Vaccine formulations used in the experiments.
Group Immunogen/adjuvant Brief description
1 Bm86 / Montanide 888 Gavac™, purified recombinant Bm86 emulsified with Montanide 888 / mineral oil.
2 Bm86 / cells Recombinant Bm86 associated to disrupted cells of P. pastoris.
3 Bm86 / membrane Recombinant Bm86 associated to the membrane of P. pastoris.
4 Bm86 / membrane / saponin Recombinant Bm86 associated to the membrane of P. pastoris.
5 Cells Cells of P. pastoris.
6 Membrane Membrane of P. pastoris.
7 Membrane / saponin Membrane of P. pastoris plus saponin.
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quantitatively and qualitatively similar antibody re-
sponses to that of Bm86 / Montanide 888 [8]. The mech-
anism by which membrane-based formulations act could
be similar to that of oil-based adjuvants [12], forming a
depot that slowly releases the antigen prolonging its per-
sistence and exposure time to immunocompetent cells.
The addition of saponin to the membrane formulation
strongly stimulated the immune response in mice, in-
creasing the IgG2/IgG1 ratio (Table 3). Similar results
have been previously reported with the use of saponin in
mice [13]. This formulation was also effective in calves,
producing a quantitatively similar response to that of
Montanide 888 (Table 4). The response elicited by the
membrane plus saponin showed an increase in the level
of IgG2 and a decrease in the amount of anti-Bm86 IgG1
antibodies. The ability of the membrane / saponin for-
mulation to potentiate the antibody response in cattle to
levels similar to those of Montanide 888 was therefore
demonstrated. However, the increase in the IgG2 re-
sponse had a negative effect on the level of protection
against tick infestation (Table 5), evidencing the role of
IgG1 antibodies in the mechanism of action of anti-tick
vaccines. In previous results animals immunized with
midgut membrane antigens from B. microplus were pro-
tected against tick populations showing a collaborative
action between the complement proteins and IgG1 anti-
bodies [10,14]. IgG1 is the isotype that most efficiently
fixes the complement in cattle [14, 15].
The inability of animals to respond to Bm86 associated
to cells could be explained by the sub-cellular localiza-
tion of the protein, which seems to be associated to the
periplasmic side of the plasma membrane being unex-
posed to the immune system. Perhaps this formulation
produces a stronger cell response, but this does not seem
to play an important role in the Bm86-mediated mecha-
nisms for the protection of cattle from B. microplus in-
festation [16].
The potential of the mouse as a predictive model of the
immune response of cattle to the recombinant antigen
Bm86 was also studied. Under experimental conditions,
the response to Bm86 could be effectively predicted. The
levels of antibodies specifically against Bm86 were pro-
portional in mice and cattle. Furthermore, there was a
high correlation between the titer of anti-Bm86 IgG1
elicited in mice and the efficacy of the formulation in cat-
tle. These results could simplify future studies in the
search of new adjuvants for the recombinant Bm86 anti-
gen.
Although the inclusion of saponin in anti-tick vaccines
should not be considered in the future because it produc-
es a reduction in the anti-Bm86 IgG1 subtype and in-
creases the IgG2a. The use of alternative yeast
derivatives as adjuvants of the immune response in cattle
are of increasing interest, particularly for antigens like
Bm86 that remain associated to the membrane. The dual
use of the yeast expression system can make this vaccine
more cost-attractive.
Materials and Methods
Preparation of P. pastoris fractions
The recombinant vaccine Gavac™ against the cattle ticks
and the genetically engineered strain of P. pastoris that
expresses the recombinant Bm86 antigen were obtained
as previously reported [1,2]. A control strain of P. pas-
toris expressing a fungal dextranase [17] was used in the
study to prepare control formulations.
Yeast cells were harvested from methanol induced cul-
tures of both strains. Cells were mechanically disrupted
with glass beads [2] or processed to purify the plasma
membrane [18]. Briefly, cells were re-suspended in dis-
ruption buffer (50 mM sodium phosphate, 5 mM EDTA,
10% sucrose, 300 mM NaCl, 1 mM β-mercaptoethanol,
pH 7) and disrupted using a ball mill disruptor. The dis-
ruption pellet was obtained by centrifugation and then
homogenized in washing buffer (50 mM sodium phos-
phate, 5 mM EDTA, 0.5% Triton X-100, 300 mM NaCL,
1 mM β-mercaptoetahnol, pH 7). The pellet was finally
recovered by centrifugation. The plasma membrane was
obtained eliminating the cell wall by treating with the hy-
drolytic enzyme Zymolase 100T (Sigma, USA) and puri-
fied by differential ultra-centrifugation on sucrose
gradients [18].
The fractions obtained were analyzed by SDS-PAGE and
Western blot. The concentration of Bm86 associated to
the cell and membrane preparations was determined to
adjust the amount of Bm86 antigen in each formulation
(Table 6) to 50 µg/ml. Equivalent amounts of the prepa-
rations from the control strain were added to obtain con-
trol vaccine formulations (Table 6). Saponin (saponin
white pure, Merck) was added to the final concentration
of 1 mg/ml when indicated.
Animals, immunization and serum collection
Experiment I
Seven groups of 5-week old Balb/c mice were randomly
distributed into four test groups and three control
groups (Table 6). Three doses of 100 µl of vaccine (test
groups containing 5 µg of Bm86) were sub-cutaneously
injected at 0, 10 and 20 days. Sera from animals were
collected on days 0, 10, 20, 30 and 40 and stored at -20°C
for a later immune response analysis.
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Five groups of 3 one- year- old Holstein calves each were
used in the experiment (Groups 1,2,4,5 and 7 in Table 6).
Animals were immunized with 100 µg of Bm86 in doses
of 2 ml by the intra-muscular route (IM) at 0, 4 and 7
weeks. Jugular blood samples were collected from cattle
at 9 weeks and stored at -20°C until they were assayed.
Immunoglobulin levels in sera
The anti-Bm86 antibodies were determined by ELISA
[19]. Briefly, 100 µl of a solution with 1 µg/ml of purified
Bm86 were dispensed into each well of Nunc Polisorp
immunoplate (MaxiSorp F96 and PolySorp F96). Plates
were coated overnight at 4°C, washed twice with PBS
containing 0.005% Tween 20 (PBST) and then blocked
with 2% skim milk (Oxoid, UK) for 1 hour at 37°C. Plates
were washed four times with PBST and 100 µl serum was
added in a serial two-fold dilution of serum in phosphate
buffer saline (PBS). Plates were incubated 2 hour at
37°C, washed with PBST and labeled with 100 µl of HRP-
conjugated goat anti-mouse IgG or sheep anti-bovine
IgG. Plates were incubated for 40 min. at 37°C, washed
four times with PBST and 100 µl of a substrate solution
(0.4 mg / ml orthophenylene diamine diluted in 0.005 M
citric acid/ 0.1 M Na2HPO4 containing 1 µl /ml 30%
H2O2 (BDH, Poole, UK) were added to each well. Color
was allowed to develop for approximately 10 min. Add-
ing 50 µl per well of 2.5 M H2SO4 terminated the reac-
tion. The optical density (OD) was measured using a
Flow Titerteck Multiskan ELISA reader equipped with a
492 nm filter.
Separation of IgG subclasses and analysis
Mouse IgG subclasses were separated based on their af-
finity to Protein A. Pooled sera from day 40 were loaded
in a column of Protein A- Sepharose-CL4B (Pharmacia,
Sweden) and the immunoglobulin subclasses were elut-
ed with a stepwise pH gradient of 0.1 M citric acid. The
subclasses obtained by affinity chromatography were
concentrated, dialyzed, and then assayed by ELISA to de-
termine the subclass-specific antibody levels to Bm86, as
described above.
Bovine subclasses were determined using goat anti-bo-
vine subclass-specific secondary antibodies (Sigma,
USA) in the ELISA analysis of the sera.
Challenge with tick larvae
Two weeks after the third immunization, calves were
controlled-infested with 1000 larvae of B. microplus
(Camcord strain) per animal per day for three days.
Adult engorged females ticks were collected, counted,
weighed and their egg laying capacity and the fertility of
the eggs were assessed [3]. The efficacy of the adjuvants
used was determined employing the following parame-
ters [1,3,5]:
Reduction on the number of adult female ticks:
% RAFT= 100 [1-(NTV/NTC)]
NTV: Number of adult female ticks in the vaccinated
group.
NTC: Number of adult female ticks in the control group.
Reduction of the weight of the engorged ticks
% RWT= 100 [1-(WTV/WTC)]
WTV: Mean weight of the adult female tick in the vacci-
nated group.
WTC: Mean weight of the adult female tick in the control
group.
Reduction of the egg laying capacity of the adult female
tick:
%RECT= 100 [1-(EWTV/EWTC)]
EWTV: Mean weight of the eggs per tick surviving in the
vaccinated group.
EWTC: Mean weight of the eggs per tick surviving in the
control group.
Reduction of fertility:
%RF = 100 [1-(WLV/WLC)]
WLV: Mean weight of the larvae per gram of eggs in the
vaccinated group.
WLC: Mean weight of the larvae per gram of eggs in the
control group.
Efficacy (%) = 100 × {1- (CRT × CRO × CRF)}; CRT: Re-
duction in the number of engorging tick; CRO: Reduc-
tion in the egg laying capacity; CRF: Reduction infertility
Statistical analyses
Differences between mean anti-Bm86 antibody titers
were determined by analysis of variance according to
Student's t test.
Correlation analysis was carried out between the anti-
body levels elicited in mice and those elicited in cattle in
order to determine the predictive value of the mouse
BMC Biotechnology (2001) 1:2 http://www.biomedcentral.com/1472-6750/1/2model for immungenicity. Relationships between the
specific level of anti-Bm86 IgG subclasses in mice and
the protection level achieved in cattle with each formula-
tion (expressed as efficacy) were also established by cor-
relation analyses.
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